Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation

Wells, Denise A.; Benesch, Martin; Loken, Michael R.; Vallejo, Carlos; Myerson, David; Leisenring, Wendy M.; Deeg, H. Joachim

doi:10.1182/blood-2002-09-2768

Cited by 319 publications

(433 citation statements)

References 40 publications

Supporting

Mentioning

390

Contrasting

Unclassified

Order By: Relevance

“…MFC is capable of identifying dysplastic features in BM samples and, thus, was supposed to be added to the diagnostic workup in patients who have suspected MDS. [13][14][15][16]32,34 In the current study, several aspects regarding the specificity and sensitivity of MFC for diagnosing MDS have been elucidated in agreement with previous studies. 15,16 In the current series and in the data reported by van de Loosdrecht et al, 16 this also is true for the identification of dysplastic features in cell lineages that were not rated dysplastic by CM alone.…”

Section: Discussionsupporting

confidence: 89%

“…[13][14][15][16] These findings have been described in MDS and do not occur or occur only infrequently in patients who have cytopenias that are not considered MDS. The objective of the current study was to estimate the potential diagnostic value of MFC.…”

mentioning

confidence: 56%

“…Although the majority of previous reports focused on patients with proven MDS and, in part, added control samples from patients who clearly did not have a malignancy, [13][14][15][16] in the current study, a large series of 1013 patients with suspected MDS was the focus of our analyses. None of these patients had undergone a prior proof or rule out of MDS.…”

Section: Discussionmentioning

confidence: 99%

“…MFC was performed by applying 5-fold stainings and using the antibodies outlined in Table 1 (selected based on previous studies). [13][14][15]28,29 Antibodies were purchased from Immunotech (Marseilles, France) except for carcinoembryonic antigen-related cell adhesion molecule 6/nonspecific cross-reacting antigen (cluster of differentiation [CD] 66c [CD66c]) (Becton Dickinson, Heidelberg, Germany). Antibody combinations were added to 10 6 mononuclear cells (volume, 100 lL) and incubated for 10 minutes.…”

Section: Multiparameter Flow Cytometrymentioning

confidence: 99%

“…The percentage of blasts was calculated by using the total amount of mononuclear cells after sample preparation as the denominator. According to previous reports, [13][14][15]28,29 the following features were evaluated. Granulocytes were evaluated for SSC signal, abnormal alanine aminopeptidase (CD13)/human neutrophil antigen 1 (CD16) and integrin a M (CD11b)/CD16 expression patterns, neural cell adhesion molecule (CD56) coexpression, 67-kDa membrane glycoprotein (CD33) negativity, and integral membrane glycoprotein (CD64) negativity.…”

Section: Gating Strategymentioning

confidence: 99%

See 4 more Smart Citations

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Kern¹,

Haferlach²,

Schnittger³

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The diagnosis and classification of myelodysplastic syndromes (MDS) is based on cytomorphology (CM) and cytogenetics (CG). Multiparameter flow cytometry (MFC) may add important diagnostic information. METHODS: To evaluate the potential role of MFC in the diagnostic setting of MDS, the authors analyzed the results from 1013 patients with suspected MDS by using CM, CG, and MFC in parallel. RESULTS: Concordance between CM and MFC was 82% for diagnostic results in 788 patients who had unequivocal CM results. An additional 225 patients had only minor dysplastic features identified by CM, including 51 patients (22.7%) who had clear evidence of MDS by MFC. Twelve patients who had no indication of MDS identified by CM had MDS-typical CG aberrations; in 6 of those patients (50%), MFC revealed MDS characteristics. In another 11 of 23 patients (47.8%) who had minor dysplastic features identified by CM and MDS-typical CG aberrations, MFC revealed MDS characteristics. The percentages of blasts determined by CM and by MFC were strongly correlated (P < .001). The frequency of aberrantly expressed antigens differed significantly between patients rated by CM as MDS (highest frequencies), suspected MDS, and no MDS (lowest frequencies). In various patients, MFC identified MDS-typical aberrant antigen expression in cell compartments that were not rated dysplastic by CM. The numbers of aberrantly expressed antigens were correlated with International Prognostic Scoring System scores and overall survival. CONCLUSIONS: The current analysis clearly demonstrated an increased diagnostic yield with MFC when added to CM and CG in patients with suspected MDS. Cancer

show abstract

Section: Discussionsupporting

confidence: 89%

mentioning

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Multiparameter Flow Cytometrymentioning

confidence: 99%

Section: Gating Strategymentioning

confidence: 99%

See 3 more Smart Citations

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Kern¹,

Haferlach²,

Schnittger³

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

Myelodysplastic Syndromes

2010

Cancer Cytogenetics

View full text Add to dashboard Cite

SynopsisThe myelodysplastic syndromes are a diverse group of clonal stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and an increased propensity to evolve to acute myeloid leukemia. The molecular pathogenesis of these disorders is poorly understood, but recurring chromosomal abnormalities occur in ~50% of cases, and are the focus of much investigation. The availability of newer molecular techniques has allowed the identification of additional genetic aberrations, including mutations and epigenetic changes of prognostic and potential therapeutic importance. This review will focus on the key role of cytogenetic analysis in MDS in the context of the diagnosis, prognosis, and pathogenesis of these disorders.Keywords myelodysplastic syndromes; cytogenetics; molecular genetics; diagnosis; prognosis; classification IntroductionThe myelodysplastic syndromes (MDS) include a large spectrum of clonal hematopoietic stem cell disorders that are characterized by peripheral cytopenia(s), morphologic dysplasia, ineffective hematopoiesis, and a variable propensity to transform to acute myeloid leukemia (AML). 1,2 The cytopenia can be limited to a single cell line resulting in anemia, This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript thrombocytopenia, or neutropenia, and can be chronic and somewhat indolent, or profound involving all three lineages with life-threatening consequences. The morphologic dysplasia associated with the ineffective hematopoiesis may be subtle and difficult to recognize but, in some cases, it can be impressive and evident in both the bone marrow and peripheral blood. The variable increase in blasts relates, in part, to the risk for transformation to AML, although progression is not solely dependent on the blast percentage. MDS is a disease of older adults with a median age at diagnosis of ~70 years 3 . Other risk factors for the development of MDS include tobacco use and exposure to solvents, such as benzene and agricultural chemicals. In ~10-15% of cases, the disease arises as a late complication of cytotoxic therapy (radiotherapy and/or chemotherapy) for a prior disorder, and is referred to as a therapy-related myeloid neoplasm (t-MN). MDS is frequently associated with clonal cytogenetic abnormalities, of significant prognostic 4,5 and emerging therapeutic importance. An in-depth analysis of some of these is providing significant insights into underlying molecular alterations, which may hold clues to unraveling the pathogenesis of these disorders. This review will focus on the ...

show abstract